Over the past several years substantial evidence has documented that opioid receptor homo-and heterodimers form in cell lines expressing one or more of the opioid receptors. We used opioid receptor knockout mice to determine whether in vivo pharmacological characteristics of kappa 1 and kappa 2 opioid receptors changed following knockout of specific opioid receptors. Using displacement of the general opioid ligand diprenorphine, we observed that occupancy or knockout of the DOR-1 gene increases the binding density of kappa 1 receptors and eliminates kappa 2 receptors in crude membrane preparations while the total density of kappa opioid binding sites is unchanged. Further, the analgesic potency of U69,593 in cumulative dose response curves is enhanced in mice lacking the DOR-1 gene. These results demonstrate that the DOR-1 gene is required for the expression of the kappa 2 opioid receptor subtype and are consistent with the possibility that a KOR-1/DOR-1 heterodimer mediates kappa 2 pharmacology.
ABSTRACT
Over the past several years substantial evidence has documented that opioid receptor homo-and heterodimers form in cell lines expressing one or more of the opioid receptors. We used opioid receptor knockout mice to determine whether in vivo pharmacological characteristics of kappa 1 and kappa 2 opioid receptors changed following knockout of specific opioid receptors. Using displacement of the general opioid ligand diprenorphine, we observed that occupancy or knockout of the DOR-1 gene increases the binding density of kappa 1 receptors and eliminates kappa 2 receptors in crude membrane preparations while the total density of kappa opioid binding sites is unchanged. Further, the analgesic potency of U69,593 in cumulative dose response curves is enhanced in mice lacking the DOR-1 gene. These results demonstrate that the DOR-1 gene is required for the expression of the kappa 2 opioid receptor subtype and are consistent with the possibility that a KOR-1/DOR-1 heterodimer mediates kappa 2 pharmacology. two classes. One class is represented by highly specific ligands such as U69,593 and U50,488 that recognize only κ opioid receptors while less selective κ opioid ligands such as ethylketocyclazocine (EKC) recognize both κ receptors as well as other opioid receptors. κ receptors have been further divided into two classes. The κ1 receptor subtype is defined as the U69,593-sensitive κ opioid receptor and the κ2 receptor subtype includes opioid receptors sensitive to general κ ligands such as EKC but insensitive to κ1, µ and δ opioid drugs (10, 11) . Studies in κ opioid receptor-1 gene (KOR-1) knockout mice demonstrate that mutation of the KOR-1 gene results in loss of both κ1 opioid receptor analgesia and binding (12, 13) . Thus, κ1 opioid receptors require the KOR-1 gene. However, study of κ2 opioid receptor pharmacology has been limited due to the lack of a drug exhibiting high specificity for only this receptor. One recent study demonstrated that all opioid receptor binding, including that characteristic of κ2 opioid receptors, is lost following deletion of all three classic opioid receptor genes (14) . Thus, the κ2 opioid receptor must be either a product of one or more of the three known opioid receptor genes or is concurrently ablated following knockout of these genes.
Over the past several years substantial evidence has documented that G protein coupled receptors can form homo-and heterodimers in cell lines expressing different G protein coupled receptors. Evidence shows dimerization of GABAa receptors, 5HT receptors, adrenergic receptors, opioid receptors as well as others in vitro (15) (16) (17) (18) .
Studies in cell lines suggest that the κ opioid receptor can form homodimers and also heterodimerize with δ opioid receptors (17, 19, 20) . These studies show that coexpression of KOR-1 and DOR-1 genes in a single cell produce activities with characteristics of the pharmacologically defined κ2 opioid receptor subtype. In contrast, expression of the KOR-1 gene alone produces only the pharmacologically defined κ1 opioid receptor subtype (17) . Behavioral studies confirm that κ and δ opioid ligands can functionally modulate each other in vivo (21, 22) . Furthermore, recent in vitro and in vivo studies of the novel κ ligand 6'GNTI, suggest that this compound may be a selective κ/δ opioid receptor heterodimer agonist (19) . Thus, both in vitro and in vivo data suggest that κ/δ opioid receptor heterodimers may form and have functional relevance.
We here have attempted to determine if the pharmacological consequences of dimerization observed in cell lines could be used to indicate potential receptor dimerization in vivo using KO models. Since studies examining opioid receptor binding in single and combinatorial opioid receptor knockout mice suggest that both κ 1 and κ 2 opioid receptors are present in mice as well as rats and require the opioid system (14), we examined the relationship between potential dimers and the classically defined κ subtypes. Finally, we confirm and extend studies suggesting that κ/δ heterodimers may have in vivo relevance by examining in vivo δ ligand modulation of κ agonist function in the presence and absence of a functional DOR-1 gene.
MATERIALS AND METHODS

Mice
All experiments were performed on male wild type and opioid receptor KO mice maintained on a 129S6 inbred background. Inbred strains bearing one opioid receptor deletion were constructed by mating original heterozygous male chimeras (5, 12, 23) with 129S6 inbred females to produce isogenic mice heterozygous for the deletions.
Mating heterozygous mice produced homozygous mutant mice and mating single homozygous mutant mice ultimately produced combinatorial mutants.
Binding studies
Crude membranes were isolated by standard procedures (23 
Saturation studies
For saturation binding, ~150 µg aliquots of frozen homogenate were incubated with 6 concentrations in duplicate of 3 H diprenorphine (Specific Activity 50-60 Ci/mmol; Perkin Elmer Life Sciences, Waltham, MA) in 50 mM Tris HCL, pH 7.4 in the presence or absence of 10 µM DPDPE for 1 hr at room temperature. 10 µM naloxone was used to define nonspecific binding. Samples were rapidly filtered onto Whatman GF/C filter paper presoaked in 0.3% BMI, washed three times with ice-cold 50 mM Tris HCL, pH 7.4 using a Brandel Cell Harvester (Brandel, Gaithersberg, MD) and counted on a Beckman LS 6500 scintillation counter (Beckman Coulter, Fullerton, CA). The resulting Kd from the saturation binding experiments was used to calculate Ki and Bmax for displacement experiments.
Displacement studies
For displacement assays saturating concentrations (~2 nM) of 3 H diprenorphine were used. 3 H diprenorphine was incubated in the presence and absence of 11 concentrations of cold U69,593, DPDPE or EKC in triplicate for 2 hr at room temperature. 10 µM naloxone was used to define nonspecific binding. Samples were prepared the same as for saturation binding experiments. Displacement curves were generated using GraphPad Prizm (Graphpad, La Jolla, CA). Curves were generated for both a one-site displacement curve as well as a two-site displacement curve. Data was assumed to be a two-site displacement only if the two-site displacement curve significantly (p<0.05) fit the data better than a one-site displacement curve. Using a K d for diprenorphine which was empirically determined in concurrent 3 H diprenorphine saturation binding experiments, Kis were determined using the Cheng-Prusoff equation (24) . The K d for diprenorphine needed to be determined for each individual experiment due to slight changes in K d between experiments. In addition, trends were observed in K d (as would be expected due to differences in receptors present) dependent on the tissue and genotype. Binding density for 3 H diprenorphine in displacement studies was determined using the binding in the absence of displacing ligand, in the presence of 10 µM naloxone and the empirically determined K d for 3 H diprenorphine.
Behavioral studies
All analgesia testing was performed using the radiant heat tailflick assay of nociception. Intensity of the beam was adjusted to yield baseline tailflick latencies between 2-3 seconds. A cut off of 10 seconds was employed to reduce tissue damage. Percent maximum possible effect (%MPE) was determined according to the following formula: (post-latency-pre-latency)/ (10-prelatency)X100.
U69,593 was initially dissolved in 10% ethanol then further diluted in normal saline (so that the final concentration of ethanol was less than 0.1%.) and all other drugs were dissolved in saline. Intrathecal (i.t.) injections were performed as described elsewhere (25) . All doses were administered in a final volume of 5 ul. Mice were injected with drug and tested for analgesia 15 minutes afterwards. For dose response curves, immediately after testing mice were injected with the next highest dose. This procedure was repeated until all doses had been administered. ED50 values were determined for each animal using a non-linear regression fit to a variable slope sigmoidal dose response curve (Graphpad Prizm, La Jolla, CA). When two drugs such as U69,593 and DPDPE were administered to the same animal, both U69,593 and DPDPE were diluted to the appropriate concentration in the same tube prior to injection.
Statistical analysis
All binding experiments were performed a minimum of 3 separate times using different membrane preparations. For derived binding density values, such as EKC-sensitive binding unaccounted for by DPDPEsensitive binding and U69,593-sensitive binding, values were obtained by subtracting the means of the DPDPEsensitive and U69,593-sensitive B max values from the EKCsensitive B max value. Variance in these derived values was determined by calculating the square root of the sum of the squared variances of the individual values used to calculate the derived value. The "n" value used for statistical analysis was the smallest "n" of the individual B max values used to determine the derived binding density. All affinities and B max values are presented as mean ± standard error of the mean. For experiments with three or more conditions, significance was determined using 2-way ANOVA with genotype and the absence or presence of a blocking ligand as factors with post-hoc analysis via Fisher's exact test. If only two conditions were compared, significance was determined using an unpaired t-test. Significance was assigned only if p<0.05.
For behavioral experiments, significance was determined for U69,593 treatment alone or in combination with δ ligands using 2-way ANOVA with genotype and treatment as factors with post-hoc analysis via Fisher's exact test. Significance was assigned only if p<0.05. U69,593 dose response curves were considered significant only if their 95% confidence intervals did not overlap.
RESULTS
Preliminary experiments using wild type and DOR-1 knockout mice demonstrated that the presence of high densities of µ opioid receptor in whole brain and spinal cord tissue reduced the sensitivity of 3 H diprenorphine binding displacement assays such that identification of κ opioid receptor subtypes was not possible (data not shown). To eliminate the possibility that the concentration of µ receptor antagonist required to block all the µ opioid receptor binding could crossreact with δ and/or κ receptors, all subsequent displacement binding experiments were conducted in mice containing a deletion of the MOR-1 gene, which decreased total opioid binding density by ~50%,but increasing the percentage of opioid binding which is κ from ~20% to ~40%. Although using mice with a deletion of the MOR-1 gene excludes the possibility that µ/κ heterodimers could contribute to the κ 2 opioid receptor subtype in vivo, no biochemical evidence to date suggests that µ/κ heterodimers can form in vitro (17) .
Characterization of κ 2 -like opioid receptor binding
We first determined the characteristics of the κ 1 -like opioid receptor binding by displacing 3 H-diprenorphine binding in whole brain membranes from MOR-1 knockout mice with increasing concentrations of U69,593. Displacement curves were biphasic ( Figure 1A ) and Hill coefficients obtained were significantly less than one, indicting two non-interacting binding sites ( Table 1) . The high affinity site detected is, by definition, the κ 1 opioid receptor subtype due to its sensitivity to U69,593 (10, 11, 26, 27) , while the low affinity site must then comprise all other opioid receptor binding sites potentially including κ 2 sites.
Next we wanted to determine if any κ 2 opioid receptors could be detected in whole brain membranes from MOR-1 KO mice. Since no specific κ 2 opioid receptor ligand exists, we instead determined the total number of opioid sites by EKC displacement of 3 H-diprenorphine and the number of δ opioid receptor sites by DPDPE displacement of 3 H-diprenorphine. The DPDPE displacement curve is also biphasic ( Figure 1B ) with Hill coefficients less than one, indicating two non-interacting binding sites (Table 1 ). The high affinity site (Kd=3.7 nM) represents displacement of 3 H-diprenorphine from δ opioid receptors. The low affinity site represents binding to all remaining opioid receptors. Finally, EKC displacement of 3 H-diprenorphine was monophasic with an affinity of 9.0 nM ( Figure 1C ) and with Hill coefficient approaching one, indicative of a single binding site ( To further verify that κ 2 opioid receptors can be detected, we displaced 3 H-diprenorphine binding with U69,593 in the presence of 10µM DPDPE. If κ 2 opioid receptors require occupancy of δ opioid receptors (as is the case for µ/δ heterodimers in vitro (28)), then 10µM DPDPE would be sufficient to eliminate all diprenorphine binding to δ opioid receptors and convert any κ 2 opioid receptor binding to a U69,593 sensitive form (17) . As predicted, U69,593 displacement of 3 H-diprenorphine in the presence of DPDPE is monophasic ( Figure 1D ) with a Hill coefficient approaching one. Furthermore, the density of binding sites displaced by U69,593 is significantly elevated in the presence of 10 µM DPDPE compared to the density of U69,593 sensitive sites detected in the absence of DPDPE (Table 1) . These results confirm that, in the presence of blocking concentrations of DPDPE, κ 2 opioid receptors respond to U69,593 in a manner indistinguishable from κ 1 opioid receptors. Furthermore, the increase in U69,593 sensitive binding (15.0 ± 4.0 fmoles/mg) is similar to the difference between the total density of opioid receptors measured by EKC displacement of 3 Hdiprenorphine and the sum of the density of κ 1 and δ opioid receptors measured by U69,593 and DPDPE displacement respectively (7.9 ± 5.0 fmoles/mg; p=0.33 EKC sensitive binding remaining following subtraction of DPDPE and U69,593 sensitive binding vs. increase in U69,593 sensitive binding in the presence of DPDPE via t-test). A similar increase was also obtained when the δ opioid receptor antagonist, TIPPψ (8.3 ± 4.5fmoles/mg; p=0.96 EKC sensitive binding remaining following subtraction of DPDPE and U69,593 sensitive binding vs. increase in U69,593 sensitive binding in the presence of TIPPψ via ttest) was used as a blocking reagent instead of DPDPE (Table 1) . Thus, these data indicate that both κ 1 and κ 2 opioid receptor subtypes exist in whole brain membranes from MOR-1 KO mice and κ 2 opioid receptor subtype is influenced by δ opioid receptor occupancy.
Knockout of DOR-1 gene eliminates κ 2 opioid receptor binding
Next we examined the possible role of δ opioid receptors in the κ 1 and κ 2 opioid receptor subtypes. Using a similar rationale as in experiments performed in whole brain membranes from MOR-1 KO mice, we displaced 3 Hdiprenorphine with U69,593 in the both the presence and absence of DPDPE in membranes from MOR-1/DOR-1 KO mice. U69,593 displacement of 3 H-diprenorphine was monophasic in whole brain membranes from MOR-1/DOR-1 KO mice independent of the presence of DPDPE ( Figure  2A & B) with a Hill coefficient approaching 1. Furthermore, we observed no significant differences in the density of binding following blockade with DPDPE (Table  1) . Thus, these data indicate thatδ opioid receptors are required for the expression of the κ 2 opioid receptor subtype. Furthermore, the number of κ 1 opioid receptors is elevated in whole brain membranes from MOR-1/DOR-1 KO mice compared to whole brain membranes from MOR-1 KO mice (Table 1) .
Similar studies using saturation binding of 3 Hdiprenorphine to whole brain membranes from MOR-1 and MOR-1/DOR-1 KO mice in the presence and absence of 10 µM DPDPE showed a significant decrease in total opioid binding following knockout of the DOR-1 gene, but no change in the total density of κ opioid receptors (Table 2) . Interestingly, the density of U69,593-sensitive sites in whole brain membranes from MOR-1/DOR-1 KO mice (44.3 ± 2.7) is significantly greater than U69,593-sensitive sites measured in the absence of DPDPE from MOR-1 KO mice (32.2 ± 2.6), but almost identical to the number of sites measured in the presence of DPDPE (47.2 ± 3.1) or TIPPψ (40.5 ± 3.6).
Knockout of the DOR-1 gene increases κ 1 opioid receptor binding in spinal cord membranes
We next examined if a similar change in κ 1 and κ 2 opioid receptor number occurs in the spinal cord of Figure 3A ) with a density of 23.0 fmoles/mg for U69,593-sensitive sites (Table 3 ). In MOR-1/DOR-1 KO mice U69,593 displacement of 3 Hdiprenorphine is monophasic ( Figure 3B ) and the density of U69,593-sensitive sites is significantly elevated to 35.2 fmoles/mg ( Table 3 ). The differences in κ 1 binding density are greater in magnitude compared to differences in κ 1 binding density in whole brain membrane preparations as expected by the greater apparent colocalization of δ and κ opioid receptors in the spinal cord (29) , but both findings suggest the same mechanism; κ 2 opioid receptors are expressed in the spinal cord of MOR-1 KO mice but are converted to κ 1 opioid receptors following knockout of the DOR-1 gene.
Knockout of the DOR-1 gene increases potency of intrathecally injected U69,593
We undertook an additional series of experiments to determine if the pharmacological changes in κ opioid receptor subtypes observed following knockout of the DOR-1 gene produced any behavioral consequences. Previous experiments examining the analgesic potency of κ ligands in DOR-1 KO mice were performed only at a single near-maximal dose (23) . Thus, we first performed cumulative dose response curves for U69,593 analgesia following i.t. injection in wild type, MOR-1, DOR-1, KOR-1 and MOR-1/DOR-1 KO mice. Consistent with the increase in κ 1 opioid receptors seen by radioligand binding studies, the i.t. potency of U69,593 significantly increases following knockout of the DOR-1 gene. The ED 50 for both DOR-1 and MOR-1/DOR-1 KO mice is significantly lower than that for wild type mice and MOR-1 KO mice, but similar to each other (Table 4 ). In KOR-1 KO mice all antinociceptive activity of U69593 is lost indicating that the KOR-1 gene is required for the κ 1 opioid receptor (Table  4) . (12) 
Co-injection of κ agonists with δ ligands enhances κ agonist intrathecal potency
Finally, we attempted to determine whether coadministration in wild type mice of a κ 1 agonist with δ ligands could mimic the enhanced U69,593 spinal analgesia observed in DOR-1 KO mice. As seen in figure 4 , coadministration of U69,593 with either a sub-activating dose of DPDPE or a non-activating dose of TIPPψ, but not naltriben, enhances U69,593 potency to approximately the same level as U69,593 injected i.t. in DOR-1 KO mice alone. In contrast, in DOR-1 KO mice, co-administration of U69,593 with any of the tested δ ligands did not change the antinociceptive potency of U69,693.
DISCUSSION
The loss of the κ 2 opioid receptor subtype in binding studies performed in membranes from MOR-1 KO mice in the presence of 10µM DPDPE or 100nM TIPPψ, or following deletion of the DOR-1 gene in MOR-1/DOR-1 KO mice indicates that the κ 2 opioid receptor subtype is dependent upon the δ opioid receptor. Additionally, the fact 1 =non-overlapping 95% confidence intervals compared to male mice with knockout in the DOR-1 gene (17) where co-expression of the DOR-1 and KOR-1 genes produced cells expressing pharmacologically defined κ 2 opioid receptors, while expression of KOR-1 alone produced only the κ 1 opioid receptor subtype and expression of DOR-1 alone produced only the δ receptor pharmacology. We demonstrate here that a similar phenomenon occurs in vivo. In MOR-1 KO mice, which express both DOR-1 and KOR-1, both κ opioid receptor subtypes (κ 1 and κ 2 ) are present, while in MOR-1/DOR-1 KO mice, which express only KOR-1, only κ 1 opioid receptors are present. Thus, the κ 2 opioid receptor subtype requires the presence of the δ opioid receptor. Furthermore, the elevation of κ 1 opioid receptor binding observed in the presence of 10µM DPDPE would be predicted based on in vitro studies that show that in the presence of DPDPE only κ 1 opioid receptor binding is detectable.
The pharmacological evidence suggesting that the κ 2 opioid receptor subtype is converted to a κ 1 opioid receptor following mutation of the DOR-1 gene led us to test whether the potency of U69,593 is enhanced in DOR-1 KO mice. As seen in Table 4 , the potency of U69,593 injected i.t is enhanced in MOR-1/DOR-1 and DOR-1 KO mice compared to wild type mice. These results are consistent with the pharmacological data indicating a 48% increase in the density of U69,593 sensitive sites in the spinal cord following knockout of the DOR-1 gene. Furthermore, these results would predict that co-injection Wild type (N=41-17) and DOR-1 KO (20-7) mice were injected intrathecally with 1 µg U69,593 alone (white bars), U69593 and 0.2 nmole DPDPE (black bars), U69,593 and 1 nmole naltriben (light grey bars) or U69,593 and 10 nmole TIPPψ (dark grey bars). *=p<0.05 vs wild type U69,593 alone. of δ and κ agonists would have a synergistic effect on their antinociceptive potency. We obtain just such a result upon co-injection of an activating dose of U69,593 and subactivating doses of DPDPE in agreement with earlier observations made by Miaskowski, et al. in 1990 (21) . Additionally, the inverse interaction also appears to be relevant. In a study by Portoghese and Lunzer, norbinaltorphimine (a κ antagonist) antagonized IT injected DPDPE, suggesting that κ/δ heterodimers not only have physiological interaction with κ agonists but also δ agonists (22) . More recently, a putative κ/δ heterodimer specific ligand, 6'-GNTI, was shown to have potency spinally but not supraspinally suggesting that κ/δ dimers may not be expressed in the brain (19) . In contrast we detect the presence of the κ 2 opioid receptor subtype in membranes prepared from whole brain tissue (Table 1) suggesting that κ/δ dimers exist supraspinally (see also (19) ), though we see no change in U69,593 potency in wild type and DOR-1 KO mice when administered supraspinally (data not shown). These results suggest that although the κ 2 opioid receptor subtype is expressed supraspinally, supraspinal κ 2 opioid receptors have no detectable role in modulation of nociception.
Although the current experiments do not biochemically demonstrate that the κ 1 opioid receptor subtype is a κ/κ homodimer and that the κ 2 opioid receptor is a κ/δ heterodimer, these results are consistent with this possibility. One alternative hypothesis is that both κ 1 and κ 2 opioid receptors are independent of the DOR-1 gene but their expression is coincidentally regulated by knockout of the DOR-1 gene. Thereby, knockout of the DOR-1 gene would effect an upregulation of κ 1 comparable to the level of κ 2 opioid receptor expression in wild type mice while simultaneously eliminating all κ 2 opioid receptor expression. Although such a reciprocal alteration in κ 1 and κ 2 opioid receptor expression seems unlikely, it cannot be ruled out. Likewise, the κ 2 opioid receptor may represent κ 1 opioid receptors uncoupled from G-protein or coupled to an alternative pathway, thereby having an altered affinity for the κ agonist, U69,593. Theoretically, then, the knockout of the DOR-1 gene or occupancy of the δ opioid receptor could free a sufficient number of G proteins to couple to the κ 2 opioid receptor and convert it to a κ 1 opioid receptor. In vivo, this possibility is less likely than in the initial studies done in heterologous cell lines. In vivo there exists a host of other G-protein coupled receptors in the membrane preparation that should be able to absorb the free Gproteins released due to the knockout or occupancy of the δ opioid receptor which would likely cause minimal change in the coupling status of the κ opioid receptor. Additionally, one can make the argument that observed increase in κ 1 binding is in fact only a more accurate sampling of the actual κ 1 binding density due to the elimination of δ binding sites. If this hypothesis were correct, one could assume that the missing binding density would be proportional to the actual binding density. The percentage increase in binding density would thus be constant between tissues even if the absolute binding density difference varied. In contrast, we observe a significant difference in binding density increases between tissue with an increase of 35% in U69,593 binding density in whole brain membranes from MOR-1/DOR-1 KO mice compared to MOR-1 KO mice but an increase of 48% in U69,593 binding density in spinal cord membranes. These results suggest that the missing binding density is not uniform between tissues and thus not likely due to a systematic error introduced by the methodology. Finally, since we did not coimmunoprecipitate homodimers and heterodimers from the mice, we cannot conclusively demonstrate that κ 2 opioid receptors are heterodimers in vivo. Nonetheless, the pharmacological changes from earlier experiments in cell lines that accompany loss of the κ/δ heterodimer do occur. In MOR-1/DOR-1 KO mice where κ/δ heterodimers cannot exist, no κ 2 opioid receptors are detectable. Likewise in MOR-1 KO mice where κ/δ dimers can exist κ 2 opioid receptors are detected. In addition, because our definition of the κ 2 opioid receptor subtype also corresponds to what is defined as the δ 1 opioid receptor subtype (19, 22) , we also suggest that the κ 2 opioid receptor subtype and δ 1 opioid receptor subtype may be the same receptor complex with δ 1 ligands recognizing the δ portion of a κ/δ heterodimer.
In most regards, our results match the results obtained by Jordan and Devi (17) in cell lines. The one difference we observe using in vivo membranes rather than in vitro membranes from cell lines is the altered response of U69,593 binding to TIPPΨ treatment. Unlike in vitro studies, TIPPΨ blockade of δ opioid receptors results in conversion of κ 2 binding sites to κ 1 binding sites in a manner similar to treatment with DPDPE (Table 1) . Our results are internally consistent in that both DPDPE and TIPPΨ coinjection with U69,593 show enhancement of analgesic potency (Table 4) . Rather, it would be more surprising if TIPPΨ did not enhance U69,593 potency considering that in other studies of opioid receptor heterodimers, such as µ/δ heterodimers, TIPPΨ does enhance both binding affinity and drug potency (30, 31) . The exact reason for this difference is unknown.
In conclusion, we have provided substantial evidence consistent with the possibility that κ 2 opioid receptors require the DOR-1 gene and potentially may be κ/δ heterodimers. After verifying the presence of both κ 1 and κ 2 opioid receptor subtypes in MOR-1 KO mice, we have been able to observe the loss of all κ 2 opioid receptor binding in MOR-1/DOR-1 KO mouse, which would be incapable of expressing a κ/δ heterodimer, or following occupation of all δ opioid receptors. Finally, we demonstrate that knockout of the DOR-1 gene or inclusion of selective δ ligands enhances the potency of a κ 1 opioid receptor agonist injected IT consistent with the hypothesis of in vivo κ heterodimers. These results support a possible simple alteration to enhance the clinical relevance of κ ligands renewing the promise of the κ opioid system as an alternative receptor system to induce antinociception and posit that co-treatment with both κ and δ ligands may be a viable method to enhance drug potency without enhancement of pharmacological side effects such as tolerance.
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